BCG vaccination in health care providers and the protection against COVID-19.
| Autor: | Netea MG; Department of Internal Medicine and Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.; Department of Immunology and Metabolism, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany., van der Meer JW; Department of Internal Medicine and Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands., van Crevel R; Department of Internal Medicine and Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of clinical investigation [J Clin Invest] 2021 Jan 19; Vol. 131 (2). |
| DOI: | 10.1172/JCI145545 |
| Abstrakt: | A number of coronavirus disease 2019 (COVID-19) vaccine candidates have shown promising results, but substantial uncertainty remains regarding their effectiveness and global rollout. Boosting innate immunity with bacillus Calmette Guérin (BCG) or other live attenuated vaccines may also play a role in the fight against the COVID-19 pandemic. BCG has long been known for its nonspecific beneficial effects that are most likely explained by epigenetic and metabolic reprogramming of innate immune cells, termed trained immunity. In this issue of the JCI, Rivas et al. add to these arguments by showing that BCG-vaccinated health care providers from a Los Angeles health care organization had lower rates of COVID-19 diagnoses and seropositivity compared with unvaccinated individuals. Prospective clinical trials are thus warranted to explore the effects of BCG vaccination in COVID-19. We posit that beyond COVID-19, vaccines such as BCG that elicit trained immunity may mitigate the impact of emerging pathogens in future pandemics. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|